Efficacy of Lu 31-130 in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S

Criteria

Inclusion Criteria:

• The patient has a primary diagnosis of schizophrenia

• The patient experiences clinically significant symptoms

• The patient did not experience an acute exacerbation requiring hospitalisation within the last 6 months

• The patient's medication has been stable for at least 4 weeks prior screening

• The subject has normal serum values of parameters associated with liver function